Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors.
Tomas Koller, Jana Kollerova, Tibor Hlavaty...
https://pubmed.ncbi.nlm.nih.gov/22182015/Actively Recruiting
Led by Pontificia Universidad Catolica de Chile · Updated on 2024-11-19
300
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating a lifestyle intervention to prevent non-alcoholic fatty liver disease NAFLD and cardiovascular disease CVD among adults aged 45 to 60, including those with gallstone disease. The study aims to improve muscle mass, aerobic capacity, body composition, lipid profiles, insulin resistance, cardiovascular risk, and maintain healthier habits through personalized exercise and dietary programs. This trial builds on findings linking gallstones and cholecystectomy to higher NAFLD and cardiovascular risks, especially in men. Participants are randomly assigned to one of two groups the control group receives standard health advice and educational materials about lifestyle and metabolic diseases, while the intervention group follows a tailored program. The intervention combines a physical exercise plan with supervised and telehealth sessions focusing on muscle strength and aerobic fitness, alongside a nutritional program emphasizing an anti-inflammatory, legume-rich diet, controlled energy intake, prolonged fasting, and sleep hygiene. The intensive phase lasts six months with frequent supervised sessions, followed by six months of telephone support and less frequent supervision to encourage adherence. Participants undergo evaluations at the start, and at 12, 24, and 36 months, including physical assessments, blood tests, liver imaging, and questionnaires about diet, sleep, depression symptoms, and quality of life. Researchers will track changes in NAFLD severity, cardiovascular risk, metabolic markers, body weight, and lifestyle maintenance. The study extends over three years to monitor long-term effects and adherence to the programs.
CONDITIONS
Prevention of NAFLD and CVD Through Lifestyle Intervention
L
Laura A Huidobro, PhD
C
Catterina Ferreccio, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Pontificia Universidad Catolica de Chile
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 week
Participants undergo baseline assessments including anthropometry, bioimpedance analysis, hepatobiliary ultrasound, Fibroscan, blood lipids, metabolic markers, and a diet survey.
1 visit (in-person)
Duration - 6 months
Participants in the intervention group receive a 6-month program of bi-weekly supervised exercise sessions and weekly telehealth exercise sessions, alongside a dietary program rich in anti-inflammatory components, legumes, and dietary fiber with controlled energy intake and healthy sleep habits. Participants in the control group receive standard prevention recommendations and counseling.
Twice-weekly supervised exercise sessions and weekly telehealth sessions for 6 months
Duration - 6 months
Participants receive six months of telephone support and bi-monthly direct supervision to reinforce adherence and identify risks for abandonment of the exercise and dietary program.
Monthly telephone support and bi-monthly in-person supervision
Duration - Up to 36 months
Participants from both intervention and control groups receive full evaluations at 12, 24, and 36 months to assess changes in metabolic and cardiovascular health.
3 visits (in-person) at months 12, 24, and 36
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Tomas Koller, Jana Kollerova, Tibor Hlavaty...
https://pubmed.ncbi.nlm.nih.gov/22182015/Yoosoo Chang, Yoo-Hun Noh, Byung-Seong Suh...
https://pubmed.ncbi.nlm.nih.gov/30469392/Rosa Casas, Emilio Sacanella, Ramon Estruch
https://pubmed.ncbi.nlm.nih.gov/25244229/I-Ching Lin, Yu-Wen Yang, Mei-Feng Wu...
https://pubmed.ncbi.nlm.nih.gov/25070766/Alexessander Couto Alves, Craig A Glastonbury, Julia S El-Sayed Moustafa...
https://pubmed.ncbi.nlm.nih.gov/30193568/Eldon A Shaffer
https://pubmed.ncbi.nlm.nih.gov/15802102/Hugo Perazzo, Isabela Benseñor, José Geraldo Mill...
https://pubmed.ncbi.nlm.nih.gov/29505553/Amy T Hutchison, Prashant Regmi, Emily N C Manoogian...
https://pubmed.ncbi.nlm.nih.gov/31002478/Taniya S Nagpal, Harry Prapavessis, Christina Campbell...
https://pubmed.ncbi.nlm.nih.gov/29214130/Shinjiro Imai
https://pubmed.ncbi.nlm.nih.gov/26118770/Pontificia Universidad Catolica de Chile
Lead Sponsor